Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: A multicenter study of 412 patients

Table 1 Clinical features of the study population

Age (yr)	52.7 ± 9.2
Sex (M/F), n (%)	339 (82.3)/73( 17.7)
Etiology: Alc./Vir./Metab./Miscel1, n (%)	136 (33.2)/236 (57.3)/ 8(2.0)/32 (7.5)
Cirrhosis (yes/no), n (%)	377 (91.5)/35 (8.5)
AFP (μg/L)	26.9 (ext: 0.5-245.240)
Number of nodules	1.8 ± 1.3 (median: 1, range: 1-11)
Maximum diameter (cm)	4.1 ± 3.1 (median: 3.4, range: 0.6-25)
Bilobar location (yes/no), n (%)	105 (25.5)/307 (74.5)
Portal or hepatic vein obstruction (yes/no) (n)	33 (8.1)/379 (91.9)
Milan Criteria (yes/no), n (%)	263 (63.8)/149(36.2)
Peri-operative treatment (yes/no), n (%)	275 (66.8)/137(33.2)
Transarterial chemoembolization (yes/no)	161 (39.2)/251 (60.8)
Pre-transplant surgery (yes/no)	42 (10.2)/370(89.8)
Pre-transplant ethanol injection (yes/no)	65 (15.8)/347 (84.2)
Post-transplant chemotherapy (yes/no)	57 (13.9)/355 (86.1)
Tumor differentiation (Well/moderate/poor), n (%)	248 (69.3)/90 (25.4)/20 (5.3)
Time on waiting list (mo)	4.4 ± 4.0 (median: 3.3, range: 0.1-32.3)
Initial immunosuppression Calcineurine inhibitors/ATG-OKT32, n (%)	357 (86.6)/55 (13.4)
Steroid-treated rejection episodes, n (%)	125 (30.5)
Maintenance immunosuppression
Cyclosporine A/tacrolimus, n (%)	284 (68.9)/128 (31.1)

¹Alc: alcohol; Vir: Viral; Metab: Metabolic; Miscel: Miscellaneous;

²ATG: anti-lymphocyte ab; OKT3: anti-CD3 ab.